alexa Lopinavir ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Meynard JL, Bouteloup V, Landman R, Bonnard P, Baillat V,

Abstract Share this page

Abstract OBJECTIVES: We evaluated a monotherapy maintenance regimen with lopinavir/ritonavir versus continuing current combined antiretroviral treatment (cART) in HIV patients with suppressed plasma HIV-1 RNA. PATIENTS AND METHODS: This was an open-label, non-inferiority, multicentre trial in 23 sites in France. Adults were randomized if they had no history of virological failure while receiving a protease inhibitor, maintained HIV-1 RNA <50 copies/mL for at least 6 months and did not change cART during the last 3 months. The primary endpoint was the proportion of patients with HIV-1 RNA <50 copies/mL at Week 48 (non-inferiority margin set at -12\%) with missing data and treatment modification considered as failure. The trial has been registered in ClinicalTrials.gov under the identifier NCT00140751. RESULTS: At Week 48, 84\% (73/87) of patients in the lopinavir/ritonavir monotherapy group met the primary endpoint compared with 88\% (87/99) in the cART group [difference, -4.0\%, lower limit of 90\% two-sided confidence interval (CI) for difference, -12.4\%]. In secondary analysis with success defined as plasma HIV-1 RNA <400 copies/mL, 87\% (76/87) of patients in the lopinavir/ritonavir monotherapy group were virologically suppressed compared with 88\% (87/99) in the cART group (difference, -0.5\%, lower limit of 90\% two-sided CI for difference, -8.5\%). If antiretroviral treatment intensification was taken into account, 91\% (79/87) of patients in the lopinavir/ritonavir monotherapy group met the primary endpoint compared with 88\% (87/99) in the cART group (difference, +2.9\%, lower limit of 90\% two-sided CI for difference, -4.5\%). Failures of lopinavir/ritonavir monotherapy did not show acquired resistance mutations in the protease gene. CONCLUSIONS: Lopinavir/ritonavir monotherapy did not achieve non-inferiority versus cART for maintaining plasma HIV-1 RNA <50 copies/mL. Nevertheless, the incidence of virological failure was low (mostly with HIV-1 RNA <400 copies/mL) and easily managed by treatment intensification. This article was published in J Antimicrob Chemother and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords